The Edge Pharmaceutical Group is a privately owned global pharmaceutical company, centred around strategic affiliations in key markets and with a strong heritage in the development, manufacturing, registration, and supply of healthcare products. As part of its global roll-out, Edge has created a specifically, and strategically, focussed structure to service the United Kingdom and Europe. Given the implications around Brexit, Edge is registered in the UK and Ireland. Our EU management team boasts more than 25 years’ hands-on experience in these pharmaceutical markets and is targeting the growth of Edge’s presence in the UK and across Europe. We are able to leverage our long-standing relationships across these complex and highly regulated markets resulting in transparent and mutually beneficial relationships. We were instrumental in obtaining the EMA registration of Enoxaparin Sodium Prefilled Syringes, leveraged off our longstanding relationship with our Chinese based manufacturer. We have the requisite expertise in the sourcing, development, manufacturing and marketing of prescription generic and branded pharmaceuticals, selective biosimilar products, as well as over-the- counter (OTC) and consumer health products. We offer our business partners a unique market access service covering various cross-market technical requirements, regulatory compliance, and commercial support to ensure all facilities, operations, and products comply with complex individual market needs.